Vancomycin Vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection

This study is currently recruiting participants.

Verified by VA Medical Center, Houston, July 2005

First Received: March 16, 2006 No Changes Posted

Sponsors and Collaborators:	VA Medical Center, Houston Baylor College of Medicine
Information provided by:	VA Medical Center, Houston
ClinicalTrials.gov Identifier:	NCT00304811

Purpose

The purpose of this study is to compare the outcome of treatment for bacteremic MRSA infection with vancomycin alone, vancomycin plus gentamicin, vancomycin plus rifampin, and vancomycin plus gentamicin and rifampin.

Condition	Intervention	Phase
Staphylococcus Aureus	Drug: Vancomycin Drug: Vancomycin plus Gentamicin Drug: Vancomycin plus Rifampin Drug: Vancomycin plus Gentamicin plus Rifampin	Phase IV

Study Type:	Interventional
Study Design:	Randomized, Single Blind, Active Control, Parallel Assignment, Efficacy Study
Official Title:	Vancomycin Vs. Vancomycin Plus Gentamycin For Treating Bacteremic Infection Due to Methicillin-Resistant Staphylococcus Aureus (MRSA)

Resource links provided by NLM:

Drug Information available for: Methicillin Rifampin Methicillin sodium Gentamicins Vancomycin Vancomycin hydrochloride

U.S. FDA Resources

Further study details as provided by VA Medical Center, Houston:

Primary Outcome Measures:

Time to defervescence (24 hours of temperature <100 degrees F)
Return of WBC to normal (<10,500)
negative blood cultures
discharge

Estimated Enrollment:

160

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years to 64 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with MRSA in a blood culture processed as standard of care at the VAMC
Patients or next of kin willing to sign consent to be randomized by social security number to one of the treatments.

Exclusion Criteria:

none

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00304811

Locations

United States, Texas
Baylor College of Medicine	Recruiting
Houston, Texas, United States, 77030
Contact: Daniel M Musher, MD 713-794-7384 dmusher@bcm.tmc.edu
Principal Investigator: Daniel M Musher, M.D.
Michael E. DeBakey Veterans Affairs Medical Center	Recruiting
Houston, Texas, United States, 77030
Contact: Daniel M Musher, M.D. 713-794-7384 dmusher@bcm.tmc.edu
Contact: Wanda Heffernan 713-794-7384 wanda.heffernan@med.va.gov
Principal Investigator: Daniel M Musher, M.D.
Sub-Investigator: Richard J Hamill, M.D.
Sub-Investigator: Nancy L Logan, M.A.
Sub-Investigator: Maria C Rodriguez-Barradas, M.D.
Sub-Investigator: Edward J Young, MD
Sub-Investigator: Rabih Darouiche, MD
Sub-Investigator: Barbara W Trautner, MD, BS

Sponsors and Collaborators

VA Medical Center, Houston

Baylor College of Medicine

Investigators

Principal Investigator:

Daniel M Musher, MD

Baylor College of Medicine, Houston VA Medical Center

More Information

No publications provided

Study ID Numbers:	H-17556
Study First Received:	March 16, 2006
Last Updated:	March 16, 2006
ClinicalTrials.gov Identifier:	NCT00304811 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by VA Medical Center, Houston:

MRSA
Methicillin Resistant Staphylococcus aureus

Study placed in the following topic categories:

Bacterial Infections
Anti-Infective Agents
Anti-Bacterial Agents
Rifampin
Staphylococcal Infections

Gram-Positive Bacterial Infections
Methicillin
Gentamicins
Vancomycin
Antitubercular Agents

Additional relevant MeSH terms:

Bacterial Infections
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Pharmacologic Actions
Antibiotics, Antitubercular
Staphylococcal Infections
Rifampin
Anti-Bacterial Agents

Protein Synthesis Inhibitors
Gram-Positive Bacterial Infections
Therapeutic Uses
Gentamicins
Vancomycin
Antitubercular Agents
Nucleic Acid Synthesis Inhibitors
Leprostatic Agents

ClinicalTrials.gov processed this record on August 24, 2009